Publication date: Jul 15, 2024
Recently updated COVID-19 mRNA vaccines encode the spike protein of the omicron subvariant XBB. 1.5 and are recommended for patients with inflammatory bowel disease (IBD) on immunosuppressive treatment. Nonetheless, their immunogenicity in patients with IBD against rapidly expanding virus variants remains unknown. This prospective multicenter cohort study is the first study to investigate the immunogenicity of XBB. 1.5-adapted vaccines in patients with IBD. Systemic and mucosal antibodies targeting the receptor-binding domains (RBDs) of the omicron subvariants XBB. 1.5, EG. 5.1, and BA. 2.86, as well as their neutralization were quantified before and two to four weeks after vaccination with monovalent XBB. 1.5-adapted mRNA vaccines. Vaccination increased levels of serum anti-RBD IgG targeting XBB. 1.5, EG. 5.1, and BA. 2.86 (1. 9-fold, 1. 8-fold, and 2. 6-fold, respectively) and enhanced corresponding neutralization responses (2. 3-fold, 3. 1-fold, and 3. 5-fold, respectively). Following vaccination, anti-TNF-treated patients had reduced virus neutralization compared to patients on treatments with other cellular targets. 11. 1% and 16. 7% of patients lacked EG. 5.1 and BA. 2.86 neutralization, respectively; all these patients received anti-TNF treatment. At mucosal sites, vaccination induced variant-specific anti-RBD IgG but failed to induce RBD-targeting IgA. Our findings provide a basis for future vaccine recommendations while highlighting the importance of frequent booster vaccine adaptation and the need for mucosal vaccination strategies in patients with IBD.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Mrna | anti-TNF therapy |
| Mucosal | BA.2.86 |
| Vaccines | COVID-19 |
| Weeks | EG.5.1 |
| inflammatory bowel disease | |
| mRNA vaccines | |
| mucosal immunogenicity | |
| omicron | |
| SARS-CoV-2 | |
| STAR SIGN study |